Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has been given an average recommendation of “Buy” by the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $3.75.

RTTR has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 26th. Maxim Group reissued a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Friday, August 4th.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. grew its holdings in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the quarter. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent filing with the SEC. 7.55% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/analysts-set-ritter-pharmaceuticals-inc-rttr-target-price-at-4-83.html.

Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 0.268% during midday trading on Friday, hitting $0.374. 1,143,772 shares of the company were exchanged. The company’s 50 day moving average price is $0.50 and its 200 day moving average price is $0.50. The firm’s market cap is $5.52 million. Ritter Pharmaceuticals has a one year low of $0.34 and a one year high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). Equities analysts expect that Ritter Pharmaceuticals will post ($0.42) EPS for the current year.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Stock Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.